Difference between revisions of "Reference Library"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
''As content accumulates, we can think about appropriate organization.'' | ''As content accumulates, we can think about appropriate organization.'' | ||
| − | *[[Media:Guidance Standards for CTs.pdf|Guidance for Industry, Standards for Clinical Trial Imaging Endpoints]], Food and Drug Administration, August 2011 | + | *[[Media:Guidance Standards for CTs.pdf|Guidance for Industry, Standards for Clinical Trial Imaging Endpoints]], Food and Drug Administration, August 2011. |
| − | + | *[[Media:Guidance biomarker qualification Aug 2011.pdf|Guidance for Industry, E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions]], Food and Drug Administration, August 2011. | |
| − | *[[Media:Guidance biomarker qualification Aug 2011.pdf|Guidance | ||
*[http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/De-identification/guidance.html Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule] | *[http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/De-identification/guidance.html Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule] | ||
Revision as of 23:41, 3 May 2016
As content accumulates, we can think about appropriate organization.
- Guidance for Industry, Standards for Clinical Trial Imaging Endpoints, Food and Drug Administration, August 2011.
- Guidance for Industry, E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions, Food and Drug Administration, August 2011.